The companies will work together to profile the interactions of one of Syngenta’s novel active compounds with the proteome in its relevant plant biological system. caprotec says that its platform allows it an unbiased evaluation of the interactions of small molecules with protein mixtures in a targeted and directed manner, thereby facilitating the identification and elucidation of tractable targets as well as accelerating the development of promising leads.Dr Jonathan Turner, CEO of caprotec, commented: “With proven applicability in the pharmaceutical and agrochemical areas, we are pleased to collaborate with Syngenta to further endorse the use of our unique platform in the challenging field of crop science.”Under the terms of the agreement, Syngenta will cover the associated research costs. caprotec will also receive success-based milestone payments. Further financial details were not disclosed.
